10 results about "Asthma copd" patented technology

The application discloses a bronchial asthma phenotype identification index screening method based on exosomeomics, comprising the following steps: acquiring bronchial asthma medical record data to construct a medical record data subset, and extracting multi-dimensional information to obtain diagnostic characteristics; generating an original feature set by using common diagnostic characteristics of different bronchial asthma phenotypes; constructing a knowledge graph according to exosomeomics related knowledge and the action mechanism of exosomes of different cell sources on bronchial asthma, screening exosome characteristics, and expanding the original feature set; constructing a feature selection task based on multi-objective optimization, obtaining exosome feature combinations of different bronchial asthma on the basis of the common diagnostic characteristics, and determining exosome identification indexes of bronchial asthma phenotypes after comparison and verification of the identification accuracy of the original common diagnostic characteristics. The exosomeomics indexes highly related to bronchial asthma diagnosis are screened, biomarkers are obtained for predicting allergic and asthma conditions, and the identification accuracy of bronchial asthma phenotypes is improved.

This invention provides a susceptibility gene for Th2-type asthma, a drug for it, and its application. The susceptibility gene is ALOX15, and the drug is an inhibitor of ALOX15 expression. This invention is the first to discover the relationship between ALOX15 and its main product, 15-HETE-PE, and Th2-type asthma. Inhibition of ALOX15 expression significantly reduces eosinophil expression and the number and percentage of eosinophils in blood and bronchoalveolar lavage fluid. Therefore, specific treatment targeting ALOX15 can serve as a novel treatment for asthma. The drug of this invention effectively reduces eosinophil count in animal and cell experiments, achieving a therapeutic effect for Th2-type asthma. This is a significant advantage compared to some refractory asthma patients whose eosinophil count cannot be reduced to normal levels with existing treatments.

The invention discloses a CGRP receptor antagonist and application thereof. The CGRP receptor antagonist has a structure as shown in a formula I, or pharmaceutically acceptable salt of the structure as shown in the formula I, and an isomer thereof. The invention also provides application of the compound shown in the formula I in preparation of medicines for preventing and / or treating related respiratory diseases such as asthma.

1. Name of the designed product: Inhaler for children with asthma (Tufannex). 2. Use of the designed product: Inhaler for asthma attack. 3. Design points of the designed product: Shape. 4. Picture or photo best indicating the design points: Perspective view.

The invention discloses application of an NTA10 inhibitor Remodelin in preparation of a medicine for treating allergic asthma, and belongs to the technical field of biological medicine. The core pathological link of the allergic asthma is macrophage M2 polarization imbalance, and NAT10 serving as RNA N4-acetylcytidine modified write enzyme can drive the polarization process. Remodelin is used as an NAT10 specific inhibitor, and can be combined with an NAT10 catalytic structural domain to inhibit the activity of acetyltransferase in a targeted manner, so that an M2 polarization signal channel of macrophages induced by IL-4 / IL-13 is blocked. The invention provides an intraperitoneal injection type medicine taking Remodelin as a core active component, and in-vivo and in-vitro experiments prove that the medicine can remarkably reduce airway inflammatory cell infiltration, down-regulate inflammatory factor release, inhibit high secretion of mucus and airway remodeling, reduce the serum IgE level and effectively improve the pathology phenotype of allergic asthma. According to the invention, the asthma treatment value of the Remodelin-NAT10-macrophage M2 polarization regulation axis is disclosed for the first time, the blank of treating asthma through targeted RNA epigenetic modification is filled, and a brand new treatment scheme is provided for severe asthma.

This invention relates to the field of pharmaceutical technology, specifically to a pharmaceutical composition for treating allergic asthma, its preparation method, and its application. The pharmaceutical composition for treating allergic asthma of this invention is obtained by combining luteolin, arbutin, and isopyramidal lactone in a specific ratio. The resulting pharmaceutical composition can significantly improve the pathological characteristics of asthma; it can improve pathological changes caused by asthma, such as bronchial stenosis, increased airway mucus, thickening of bronchial smooth muscle, and a large number of inflammatory cells around the airways; it can reduce lung inflammation caused by allergic asthma; it can improve airway remodeling in allergic asthma; it can reduce lung tissue apoptosis and lung damage caused by allergic asthma; it can alleviate the symptoms of allergic asthma and has a protective effect against allergic asthma. It can be used in the preparation of asthma drugs, anti-allergic inflammatory drugs, and drugs that reduce lung tissue apoptosis.

The present invention relates to a composition for co-administering Belzutifan, which is an HIF-2ɑ activity inhibitor having a steroid-resistant allergic airway inflammation reduction effect, and a steroid. The composition according to the present invention has the effect of alleviating inflammation and symptoms by co-administering an HIF-2ɑ inhibitor during the treatment of severe allergic asthma patients exhibiting steroid resistance. Thus, co-administering Belzutifan, which is an HIF-2ɑ inhibitor, and a steroid is a more effective treatment that can alleviate asthma and increase the quality of life of severe asthma patients.

The invention provides an asthma susceptibility gene, a medicine thereof and application of the medicine. The susceptibility gene is SGLT2. The medicine is an inhibitor canagliflozin of SGLT2. The potential causal association between the hypoglycemic drug canagliflozin and the asthma risk is found for the first time, the canagliflozin can significantly improve Th2 type airway inflammation, goblet cell metaplasia and pulmonary interstitial collagen deposition, the treatment effect is significant, and the anti-inflammatory protection effect is related to a PI3K / AKT pathway.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of asthma. The TCM composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that the TCM composition provided by this invention can effectively improve airway hyperresponsiveness, reduce lung resistance, and enhance dynamic lung compliance in asthma model animals. Simultaneously, it can significantly reduce the content of pro-inflammatory factors IL-4 and IL-13 in the bronchoalveolar lavage fluid of asthma models, alleviate airway inflammation, and relieve asthma pathological symptoms. It can stably exert its effect in preventing and treating asthma, and its efficacy is stable and its safety is good. It can be further developed into a drug for the prevention and treatment of asthma and has good clinical application prospects.

The invention discloses an asthma condition grading prediction method combining monitoring data and molecular markers. The method comprises the following steps: step 1, obtaining a plurality of types of sample data; 2, performing time sequence alignment on the sample data; 3, based on the quality evaluation factor of each category of collected data, the quality evaluation factor represents the credibility of the collected data, and the weight of each category of collected data is determined; 4, performing feature engineering extraction on the sample data to obtain feature engineering data of a plurality of types of core features; 5, the feature engineering data are input into a preset model for risk level prediction, a risk score is obtained, the risk level of the asthmatic attack is determined based on the risk score, and the risk level comprises a high risk level, a medium risk level and a low risk level. According to the invention, the asthma attack risk level can be identified as early as possible and more accurately, data support is provided for subsequent diagnosis and treatment, and subsequent disease control is facilitated.